A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma

BACKGROUND: Survival for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapies. AIMS: To study the feasibility and safety of incorporating a genomic‐based targeted agent to induction therapy for HRNB as well as the feasibility and safety of adding difluoro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraveka, Jacqueline M., Lewis, Elizabeth C., Bergendahl, Genevieve, Ferguson, William, Oesterheld, Javier, Kim, Elizabeth, Nagulapally, Abhinav B., Dykema, Karl J., Brown, Valerie I., Roberts, William D., Mitchell, Deanna, Eslin, Don, Hanson, Derek, Isakoff, Michael S., Wada, Randal K., Harrod, Virginia L., Rawwas, Jawhar, Hanna, Gina, Hendricks, William P. D., Byron, Sara A., Snuderl, Matija, Serrano, Jonathan, Trent, Jeffrey M., Saulnier Sholler, Giselle L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675391/
https://www.ncbi.nlm.nih.gov/pubmed/35355452
http://dx.doi.org/10.1002/cnr2.1616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675391/
https://www.ncbi.nlm.nih.gov/pubmed/35355452
http://dx.doi.org/10.1002/cnr2.1616

Ejemplares similares